299 related articles for article (PubMed ID: 26493004)
1. Consideration of non-linear, non-threshold and threshold approaches for assessing the carcinogenicity of oral exposure to hexavalent chromium.
Haney J
Regul Toxicol Pharmacol; 2015 Dec; 73(3):834-52. PubMed ID: 26493004
[TBL] [Abstract][Full Text] [Related]
2. Implications of dose-dependent target tissue absorption for linear and non-linear/threshold approaches in development of a cancer-based oral toxicity factor for hexavalent chromium.
Haney J
Regul Toxicol Pharmacol; 2015 Jul; 72(2):194-201. PubMed ID: 25910675
[TBL] [Abstract][Full Text] [Related]
3. Integration of mechanistic and pharmacokinetic information to derive oral reference dose and margin-of-exposure values for hexavalent chromium.
Thompson CM; Kirman CR; Hays SM; Suh M; Harvey SE; Proctor DM; Rager JE; Haws LC; Harris MA
J Appl Toxicol; 2018 Mar; 38(3):351-365. PubMed ID: 29064106
[TBL] [Abstract][Full Text] [Related]
4. A chronic oral reference dose for hexavalent chromium-induced intestinal cancer.
Thompson CM; Kirman CR; Proctor DM; Haws LC; Suh M; Hays SM; Hixon JG; Harris MA
J Appl Toxicol; 2014 May; 34(5):525-36. PubMed ID: 23943231
[TBL] [Abstract][Full Text] [Related]
5. Comparison of in vivo genotoxic and carcinogenic potency to augment mode of action analysis: Case study with hexavalent chromium.
Thompson CM; Bichteler A; Rager JE; Suh M; Proctor DM; Haws LC; Harris MA
Mutat Res Genet Toxicol Environ Mutagen; 2016 Apr; 800-801():28-34. PubMed ID: 27085472
[TBL] [Abstract][Full Text] [Related]
6. Development of a cancer-based chronic inhalation reference value for hexavalent chromium based on a nonlinear-threshold carcinogenic assessment.
Haney JT; Erraguntla N; Sielken RL; Valdez-Flores C
Regul Toxicol Pharmacol; 2012 Dec; 64(3):466-80. PubMed ID: 23103602
[TBL] [Abstract][Full Text] [Related]
7. Use of dose-dependent absorption into target tissues to more accurately predict cancer risk at low oral doses of hexavalent chromium.
Haney J
Regul Toxicol Pharmacol; 2015 Feb; 71(1):93-100. PubMed ID: 25445295
[TBL] [Abstract][Full Text] [Related]
8. A quantitative assessment of the carcinogenicity of hexavalent chromium by the oral route and its relevance to human exposure.
Stern AH
Environ Res; 2010 Nov; 110(8):798-807. PubMed ID: 20843510
[TBL] [Abstract][Full Text] [Related]
9. Review of the evidence regarding the carcinogenicity of hexavalent chromium in drinking water.
Sedman RM; Beaumont J; McDonald TA; Reynolds S; Krowech G; Howd R
J Environ Sci Health C Environ Carcinog Ecotoxicol Rev; 2006 Apr; 24(1):155-82. PubMed ID: 16690539
[TBL] [Abstract][Full Text] [Related]
10. A search for thresholds and other nonlinearities in the relationship between hexavalent chromium and lung cancer.
Park RM; Stayner LT
Risk Anal; 2006 Feb; 26(1):79-88. PubMed ID: 16492182
[TBL] [Abstract][Full Text] [Related]
11. Carcinogenicity and mode of action evaluation for alpha-hexachlorocyclohexane: Implications for human health risk assessment.
Bradley AE; Shoenfelt JL; Durda JL
Regul Toxicol Pharmacol; 2016 Apr; 76():152-73. PubMed ID: 26713892
[TBL] [Abstract][Full Text] [Related]
12. Weight of evidence analysis of the tumorigenic potential of 1,3-dichloropropene supports a threshold-based risk assessment.
Yan ZJ; Bartels M; Gollapudi B; Driver J; Himmelstein M; Gehen S; Juberg D; van Wesenbeeck I; Terry C; Rasoulpour R
Crit Rev Toxicol; 2020 Nov; 50(10):836-860. PubMed ID: 33528302
[TBL] [Abstract][Full Text] [Related]
13. Assessment of the mode of action for hexavalent chromium-induced lung cancer following inhalation exposures.
Proctor DM; Suh M; Campleman SL; Thompson CM
Toxicology; 2014 Nov; 325():160-79. PubMed ID: 25174529
[TBL] [Abstract][Full Text] [Related]
14. Estimates of cancer potency of 2,3,7,8-tetrachlorodibenzo(p)dioxin using linear and nonlinear dose-response modeling and toxicokinetics.
Simon T; Aylward LL; Kirman CR; Rowlands JC; Budinsky RA
Toxicol Sci; 2009 Dec; 112(2):490-506. PubMed ID: 19776211
[TBL] [Abstract][Full Text] [Related]
15. Toxicogenomics and cancer risk assessment: a framework for key event analysis and dose-response assessment for nongenotoxic carcinogens.
Bercu JP; Jolly RA; Flagella KM; Baker TK; Romero P; Stevens JL
Regul Toxicol Pharmacol; 2010 Dec; 58(3):369-81. PubMed ID: 20801182
[TBL] [Abstract][Full Text] [Related]
16. NTP toxicity studies of sodium dichromate dihydrate (CAS No. 7789-12-0) administered in drinking water to male and female F344/N rats and B6C3F1 mice and male BALB/c and am3-C57BL/6 mice.
Bucher JR
Toxic Rep Ser; 2007 Jan; (72):1-G4. PubMed ID: 17342194
[TBL] [Abstract][Full Text] [Related]
17. Are tumor incidence rates from chronic bioassays telling us what we need to know about carcinogens?
Gaylor DW
Regul Toxicol Pharmacol; 2005 Mar; 41(2):128-33. PubMed ID: 15698536
[TBL] [Abstract][Full Text] [Related]
18. Investigation of the mode of action underlying the tumorigenic response induced in B6C3F1 mice exposed orally to hexavalent chromium.
Thompson CM; Proctor DM; Haws LC; Hébert CD; Grimes SD; Shertzer HG; Kopec AK; Hixon JG; Zacharewski TR; Harris MA
Toxicol Sci; 2011 Sep; 123(1):58-70. PubMed ID: 21712504
[TBL] [Abstract][Full Text] [Related]
19. Carcinogenicity of hexavalent chromium.
Holmes AL; Wise SS; Wise JP
Indian J Med Res; 2008 Oct; 128(4):353-72. PubMed ID: 19106434
[TBL] [Abstract][Full Text] [Related]
20. A review of mammalian
Thompson CM; Aardema MJ; Heintz MM; MacGregor JT; Young RR
Crit Rev Toxicol; 2021 Nov; 51(10):820-849. PubMed ID: 35060824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
